Welcome to our dedicated page for BeyondSpring SEC filings (Ticker: BYSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BeyondSpring Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on cancer therapies, including Plinabulin development, financial results and capital structure. Its Form 10-K and Form 8-K disclosures cover audited consolidated financial statements, quarterly and annual operating results, clinical-program updates, and risk and business information tied to oncology development.
Current reports also record material agreements, registered offerings of ordinary shares, SEED Therapeutics financing and ownership disclosures, and shareholder-vote results from annual meetings. These filings describe governance actions, securities issuances, registration-statement use and other material events affecting BeyondSpring’s public-company reporting.
BeyondSpring Inc. (BYSI) reported that on September 17, 2026 it received a notice from the Nasdaq Listing Qualifications Department that its ordinary shares no longer meet the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
The notice does not immediately delist the shares, and trading on Nasdaq continues. BeyondSpring has 180 calendar days, until March 16, 2027, to regain compliance. Compliance will be restored if the closing bid price is at or above $1.00 for at least 10 consecutive business days. The company may qualify for an additional 180-day period but states there is no assurance it will regain or maintain compliance.
BeyondSpring Inc. (BYSI) is calling its 2026 Annual General Meeting of Shareholders for October 13, 2026 at 9 a.m. Eastern Time in Florham Park, New Jersey, with virtual participation and voting available. Holders of ordinary shares at the close of business on August 24, 2026 may vote, with each share entitled to one vote and a quorum requiring at least a majority of the paid up voting share capital present in person or by proxy.
The sole proposal is ratification of the Audit Committee’s selection of CBIZ as independent registered public accounting firm for the fiscal year ending December 31, 2026, which the board unanimously recommends shareholders approve by simple majority of votes cast. The proxy materials are being distributed primarily via Internet access, with paper or email copies available on request, and Internet voting closes at 11:59 p.m. Eastern Time on October 12, 2026.
BeyondSpring Inc. major shareholders Ever Regal Group, Fairy Eagle Investments, Rosy Time Holdings, Lan Huang and Linqing Jia report their updated ownership of the company’s Ordinary Shares. The disclosure is an amendment to a prior Schedule 13G group filing.
Lan Huang and Linqing Jia each report 5,293,444 Ordinary Shares beneficially owned, representing 12.9% of BeyondSpring’s 41,119,820 Ordinary Shares outstanding as of June 30, 2026. Their holdings are aggregated through British Virgin Islands entities, GRATs, irrevocable trusts for Dr. Huang’s children, and shares held by unaffiliated third parties over which they have been granted voting proxies.
Ever Regal, Fairy Eagle, and Rosy Time each hold 2, 1, and 1 Ordinary Shares, respectively, reflecting 0.00% of the class. On June 19, 2026, Dr. Huang ceased serving on the board of Sincere Efforts Foundation Inc., after which neither Dr. Huang nor Mr. Jia is deemed to share voting or dispositive power over Ordinary Shares held by that entity.
BeyondSpring Inc. reported another loss-making quarter as a clinical-stage biotech with no product revenue. For the six months ended June 30, 2026, consolidated net loss was $12.4 million, and accumulated deficit reached $411.4 million. Continuing operations held $6.5 million of cash and short-term investments and had net current liabilities of $4.3 million, resulting in a total shareholders’ deficit of $36.0 million.
Management disclosed that recurring losses, limited liquidity and negative working capital raise substantial doubt about the ability to continue as a going concern. The company is cutting spending and seeking additional capital; failure to do so could force reductions in R&D or suspension of operations. Discontinued SEED operations generated $1.0 million of collaboration revenue but a $8.3 million loss in the first half. BeyondSpring expects to collect an additional $28.07 million in tranches from the sale of SEED preferred shares while retaining a minority stake and continuing to focus its main Plinabulin oncology program.
BeyondSpring Inc. reported second-quarter 2026 results and highlighted new clinical data for its lead asset, Plinabulin, in metastatic non-small cell lung cancer (NSCLC). Updated Phase 2 ASCO 2026 data showed a 58.0% two-year overall survival (OS) rate in post–immune checkpoint inhibitor patients, with median progression-free survival of 7.0 months and a generally manageable safety profile. Preclinical AACR 2026 data suggested Plinabulin may enhance the efficacy and tolerability of certain antibody-drug conjugates.
The company is preparing DUBLIN-4, a planned 442-patient confirmatory Phase 3 study of Plinabulin plus docetaxel in non-squamous, EGFR wild-type NSCLC after PD-1/PD-L1 therapy. A leadership transition effective July 1, 2026 installed Min Qiu as Chief Executive Officer, with a mandate focused on advancing DUBLIN-4 and financing activities.
From continuing operations, second-quarter 2026 research and development expenses were $1.0 million, and general and administrative expenses were $0.8 million, leading to a net loss of $1.8 million. For the six months ended June 30, 2026, net loss from continuing operations was $4.1 million. Cash, cash equivalents, and short-term investments totaled $6.5 million as of June 30, 2026, while total liabilities were $50.6 million against total assets of $14.6 million, resulting in a shareholders’ deficit.
BeyondSpring Inc. director Majeti Jiangwen received a grant of stock options to buy 100,000 ordinary shares. The options carry an exercise price of $1.75 per share and expire on July 1, 2036.
According to the grant terms, the options vest in four equal 25% installments on the first, second, third and fourth anniversaries of July 1, 2026, as long as the director continues to serve the company. This is a compensation-related award rather than an open-market share purchase or sale.
BeyondSpring Inc. granted its Chief Executive Officer, Qiu Min, stock options as part of compensation. The award covers 100,000 stock options to purchase ordinary shares at an exercise price of $1.75 per share, expiring on July 1, 2036.
The options were granted for no cash cost to the CEO and will vest in four equal 25% installments on the first, second, third, and fourth anniversaries of July 1, 2026, contingent on continued service with the company. Following this grant, the filing shows 100,000 derivative securities held from this award.
BeyondSpring Inc. reported the initial share holdings of its Chief Executive Officer, Qiu Min, in a Form 3 filing. The filing shows direct ownership of 2,498 Ordinary Shares after the reported entry. This is a baseline disclosure of existing ownership rather than a new buy or sell transaction.
BeyondSpring Inc. filed an initial Form 3 for Chief Financial Officer Li Na (NL), serving as the first formal statement of her beneficial ownership status in the company. The data provided shows no reportable transactions, acquisitions, or derivative positions for this reporting person in this filing.